Castle Biosciences Inc (CSTL) Q4 2025 Earnings Call Transcript

Why It Matters

Strong test‑volume growth validates Castle’s clinical value proposition, yet margin compression and losses underscore the need for disciplined cash deployment as it expands its pipeline.

Key Takeaways

• Revenue $344.2M, 2026 guide $340‑350M.
• TissueCypher volume +86%, total reports 105k.
• Net loss $24.2M; adjusted gross margin down.
• Advanced ADTX test 500 orders, revenue immaterial 2026.
• $299.5M cash reserves support pipeline investments.

Pulse Analysis

Castle Biosciences’ 2025 earnings highlight a pivotal shift toward high‑growth molecular diagnostics in dermatology and gastroenterology. TissueCypher’s 86% volume jump reflects growing clinician confidence in prognostic testing for Barrett’s esophagus, a condition linked to rising esophageal adenocarcinoma rates. DecisionDx‑Melanoma’s steady 9% increase and expanding clinician base further cement Castle’s foothold in oncology, leveraging an expanding evidence base of 58 peer‑reviewed publications to drive adoption. Together, these core franchises illustrate how targeted genomic assays can capture market share in niche, high‑value care pathways.

Financially, the company’s top‑line outperformance masks underlying pressure on profitability. Adjusted gross margin slipped to 79.8% from 81.2% a year earlier, while a one‑time amortization charge eroded overall margin to 69.2% for the year. Despite a $24.2 million net loss, Castle’s balance sheet remains robust, with nearly $300 million in cash and marketable securities. This liquidity provides runway for strategic investments, including the ProVise acquisition and the Cybase collaboration, while cushioning the impact of short‑term cash burn from expanded sales teams and R&D spend.

Looking ahead, Castle’s pipeline and commercial strategy aim to diversify revenue beyond its legacy tests. The limited‑access launch of the advanced ADTX atopic dermatitis assay generated rapid clinician interest—500 orders in five weeks—yet management cautions that meaningful revenue won’t materialize until 2027‑2028. Parallel efforts to secure FDA clearance for a non‑endoscopic GI sampling device and to evaluate electrical impedance spectroscopy for dermatitis flares could unlock new indications and broaden the addressable market. Combined with disciplined M&A targeting near‑term, reimbursable diagnostics, Castle is positioning itself to sustain double‑digit growth while navigating margin challenges.